Postherpetic Neuralgia - Pipeline Review, H2 2011

Global Markets Direct, October 2011, Pages: 72

Postherpetic Neuralgia - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Postherpetic Neuralgia - Pipeline Review, H2 2011', provides an overview of the Postherpetic Neuralgia therapeutic pipeline. This report provides information on the therapeutic development for Postherpetic Neuralgia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia. 'Postherpetic Neuralgia - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Postherpetic Neuralgia.
- A review of the Postherpetic Neuralgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Postherpetic Neuralgia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Postherpetic Neuralgia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Postherpetic Neuralgia pipeline depth and focus of Postherpetic Neuralgia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Postherpetic Neuralgia Overview
Therapeutics Development
An Overview of Pipeline Products for Postherpetic Neuralgia
Postherpetic Neuralgia Therapeutics under Development by Companies
Postherpetic Neuralgia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Postherpetic Neuralgia Therapeutics - Products under Development by Companies
Postherpetic Neuralgia Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Postherpetic Neuralgia Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Allergan, Inc.
ZARS Pharma, Inc.
XenoPort, Inc.
Pfizer Inc.
EpiCept Corporation
NeurogesX, Inc.
Xenon Pharmaceuticals Inc.
Arcion Therapeutics, Inc.
Solace Pharmaceuticals
Kalypsys, Inc.
Bial Group
KAI Pharmaceuticals Inc.
Winston Pharmaceuticals, Inc.
Spinifex Pharmaceuticals Pty Limited
Postherpetic Neuralgia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Horizant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Flexicaine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stedesa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SLC022 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NGX-1998 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epicept NP-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Civamide Nasal Solution - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Topical XEN402 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KD7040 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Civamide Patch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KAI-1678 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AGN-214868 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pregabalin + PF-00489791 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XPF-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Varicella-Zoster Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EMA401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-954561 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATx08-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNS020QD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epikeia + Aspirin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epikeia + Lidocaine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARC 2022 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Postherpetic Neuralgia Therapeutics – Drug Profile Updates
Postherpetic Neuralgia Therapeutics - Discontinued Products
Postherpetic Neuralgia - Featured News
Sep 19, 2011: Spinifex Announces Start Of Phase II Proof-of-Concept Trial Of EMA401 In Postherpetic Neuralgia
Aug 09, 2011: GSK And XenoPort Submit Supplemental New Drug Application To FDA For Horizant In Postherpetic Neuralgia
May 02, 2011: Xenon’s XEN402 Ointment Significantly Relieves Pain In Patients With Post Herpetic Neuralgia
Mar 02, 2011: Syntaxin's Partner Allergan Initiates Two Phase II Trials With Re-Targeted Endopeptidase Drug
Feb 23, 2011: Aestus Initiates Phase II Clinical Trial Of ATx08-001 In Neuropathic Pain
Feb 09, 2011: NeurogesX To Provide Qutenza Launch Update
Nov 19, 2010: NeurogesX Receives Qutenza-Specific J-Code From Centers For Medicare And Medicaid Services
Aug 17, 2010: Xenon Initiates Phase II Clinical Trial Of XEN 402 In Post Herpetic Neuralgia Patients
Jul 27, 2010: NeurogesX Progresses On Coverage For Qutenza
Jun 11, 2010: Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica Capsules on June 22
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Postherpetic Neuralgia - Pipeline Review, H1 2013
• Postherpetic Neuralgia (PHN) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
• Postherpetic Neuralgia - Pipeline Review, Q4 2010
• Global Neuralgia Drug Pipeline Capsule - 2012 Update
• Treatment Algorithms: Postherpetic Neuralgia – Lyrica forms the cornerstone of treatment for postherpetic neuralgia
• The Top 50 Developers Of Pain Management Pharmaceuticals Worldwide
• Trigeminal Neuralgia Therapeutics - Pipeline Assessment and Market Forecasts to 2019
• Winston Pharmaceuticals, Inc. - Product Pipeline Review - 2012
• Pain Therapeutics - Drugs, Markets and Companies
• Competitor Analysis: Herpes Virus Vaccines and Therapeutics